Izalontamab Brengitecan (Iza-Bren), a First-in-Class EGFR-HER3 Bispecific Antibody-Drug Conjugate in Extensive-Stage Small Cell Lung Cancer: Results From a Phase Ib Study
Yuanyuan Zhao, Hongyun Zhao, Qiming Wang, Kunyu Yang, Yongsheng Li, Zhenming Fu, Weihua Yang, Zhiyong He, Yongsheng Wang, Yuxiang Ma, Yunpeng Yang, Wenfeng Fang, Sa Xiao, Hai Zhu, Yi Zhu, Li Zhang, Yan Huang · 2026
Read Izalontamab Brengitecan (Iza-Bren), a First-in-Class EGFR-HER3 Bispecific Antibody-Drug Conjugate in Extensive-Stage Small Cell Lung Cancer: Results From a Phase Ib Study by Yuanyuan Zhao, Hongyun Zhao, Qiming Wang, Kunyu Yang, Yongsheng Li, Zhenming Fu, Weihua Yang, Zhiyong He, Yongsheng Wang, Yuxiang Ma, Yunpeng Yang, Wenfeng Fang, Sa Xiao, Hai Zhu, Yi Zhu, Li Zhang, Yan Huang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13623066.txt.
Description
Yuanyuan Zhao leads the author list of a 2026 phase one trial report for a new drug against extensive-stage small cell lung cancer. The cancer is aggressive, with few options once first treatment fails. The drug, izalontamab brengitecan, joins an antibody that homes to two receptors on tumour cells with a cell-killing payload. Patients had already progressed on earlier therapy.
Fifty-two patients received the drug on two days of each three-week cycle. Nearly half saw their tumours shrink, and results looked strongest in the twenty-two patients treated right after first-line therapy, where most responded and survival ran longest. Low blood cell counts were the most common side effects, matching the drug class. A marker test hinted that tumours carrying more of one target receptor responded better. A phase three trial comparing the drug with a standard is under way, the authors note.
Catalog record
| CREATOR | Yuanyuan Zhao, Hongyun Zhao, Qiming Wang, Kunyu Yang, Yongsheng Li, Zhenming Fu, Weihua Yang, Zhiyong He, Yongsheng Wang, Yuxiang Ma, Yunpeng Yang, Wenfeng Fang, Sa Xiao, Hai Zhu, Yi Zhu, Li Zhang, Yan Huang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 28761 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |